Indiana University
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Indiana University sits in the top decile of US sponsors by registered trial count (#38 of 15,742 sponsors by registered trial count).
Indiana University: 890 sponsored US clinical trials, 156 recruiting.
Indiana University sponsors 890 registered US clinical trials on ClinicalTrials.gov, 156 of them currently recruiting, and 561 completed. 104 of these trials are in Phase 3-4 (later-stage) and 126 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Alzheimer Disease, with 11 trials.
Top-decile sponsor footprint
Indiana University ranks in the top decile of sponsors by registered trial count (#38 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
561 of 688 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
890 total, page 1 of 18
Overground Virtual Reality (VR) Gait Rehabilitation for Stroke
NCT07676578
Effects of Replacing High Protein Foods in People With Chronic Kidney Disease
NCT07105670
Effect of Gastric Electrical Stimulation on Serum Insulin Levels
NCT07635576
Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension
NCT07588152
Circulating Tumor DNA in Stage I, II, and III Germ-Cell Tumors
NCT07401316
Pharmacokinetics and Placental Transfer of Caffeine
NCT07570121
Miniaturized Breath-based Sensor for the Detection of Hypo- and Hyperglycemia
NCT07696273
Temporal Interference Methods for Non-invasive Deep Brain Stimulation, Study 1.3
NCT07594795
rTMS Induced Reduction in M1 Excitability
NCT07588113
Respiratory and Real-time Dynamics in Exercise-Induced Paradoxical Vocal Fold Motion
NCT07420530
The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV
NCT07226128
Comparative Assessment of Lipid Layer Thickness Measurements
NCT07579130
Point-of-care Ultrasound Utility in the Free Clinic Setting
NCT07556341
The Effect of Respiratory Muscle Training on Cognitive Performance
NCT07637331
Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study
NCT07676565
Virtual Reality Cognitive Intervention for Critically Ill Delirium Survivors (VR-Cog)
NCT07496255
Assessing Pain and Effectiveness of Carevix Device for IUD Insertions
NCT07290517
Caring for Caregivers
NCT07486037
Multi-site Study to Look at Tooth Wear and Tooth Sensitivity and the Risk Factors Associated.
NCT07195357
SYSTANE® PRO vs. MIEBO™ in Dry Eye Disease
NCT07243275
Racial Disparities in the Expression of Paranoia
NCT07460453
The Role of Heliox in Respiratory Control
NCT07424014
Temporal Interference Methods for Non-invasive Deep Brain Stimulation, Study 1.2
NCT07339072
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men
NCT07161973
Temporal Interference Methods for Addiction Treatment
NCT07210268
Neuroimaging of Adolescent Cannabis Use Treatment
NCT07340554
Handheld Point of Care Electro-Diagnostic Device
NCT07223827
Concordance and Discordance in the Assessment of Volume Status in Home Dialysis Patients: A Comparison of Modified Medical Research Council Dyspnea Scale, Physical Exam, and Point of Care Ultrasound (POCUS)
NCT07178470
Foot Strengthening to Improve Balance and Gait in Older Adults
NCT07384754
Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy
NCT07336381
Temporal Interference Methods for Non-invasive Deep Brain Stimulation, Study 1.1
NCT07215299
Maintenance Zanzalintinib With Etoposide After HDCT in GCT
NCT06937866
Drug Interaction Potential of Pro-Inflammatory Conditions
NCT07360938
RaDIANT Health Systems Intervention
NCT07033117
SPARK Healthy Sleep
NCT07119268
Monitoring Exhaled Breath to Noninvasively Detect Glycemic Events
NCT06893341
Palliative Care for People With HF
NCT07356843
Sensor Ankle Brace for Special Operations Rehabilitation
NCT07085416
Cartilage Remodeling Using Low-Temperature Radiofrequency for Nasal Airway Reconstruction
NCT07032675
VisionApp - Ghosting
NCT07571538
The New Empowerment After eXposure to Trauma (NEXT) Study
NCT07175025
Pilot Randomized Clinical Trial of Informational Support Versus Spiritual Care
NCT07176559
Effects of Dietary Nitrate in Women With Secondary Amenorrhea
NCT07019129
Multi-modal Large Language Model-Empowered Talk Therapy for Older Adults With ADRD
NCT07499570
Prebiotics (Dried Plum) and Immune Function in Postmenopausal Women
NCT07222111
Guanfacine for Alcohol Use Disorder (AUD)
NCT06629259
Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0
NCT06725550
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
NCT07128095
Evaluating Caregiver Involvement in Primary Care-Based Brief Interventions for Adolescent Alcohol Use Problems
NCT06593652
Utility of Trypsinogen -2 in Early Detection and Follow Up of Post-pancreatectomy Acute Pancreatitis (PPAP)
NCT06903676
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 56 |
| Phase 2 | 70 |
| Phase 3 | 28 |
| Phase 4 | 76 |
Therapeutic Areas
What is open in the Indiana University pipeline
156 recruiting of 890 indexed (18% open); 561 completed (63%).
Phase mix: 104 late (III/IV) vs 126 early (I/II) (balanced across stages).
Top condition: Alzheimer Disease (11 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Indiana University: open-pipeline peers nationwide
Peers matched on 890 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
Indiana University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 890 trials (± recruiting share)
- University of California, Los Angeles · 897 trials · 18% recruiting
- Hoffmann-La Roche · 909 trials · 8% recruiting
- Brigham and Women's Hospital · 937 trials · 15% recruiting
- University of Texas Southwestern Medical Center · 837 trials · 19% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Edwards Lifesciences · 18% recruiting · 57 trials
- University of South Florida · 17% recruiting · 252 trials
- VA Office of Research and Development · 17% recruiting · 1,668 trials
- ConvaTec · 18% recruiting · 17 trials
Related
What to do with this Indiana University page
890 registered trials is a research-attention snapshot, not an endorsement of Indiana University or any single study.
- 156 of Indiana University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Alzheimer Disease is the condition Indiana University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Alzheimer Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Indiana University pipeline card: 890 registered trials from official public datasets.Report a data error.